Assertio Therapeutics (ASRT) Tops Q1 EPS by 5c

Assertio Therapeutics (NASDAQ: ASRT) reported Q1 EPS of $0.23, $0.05 better than the analyst estimate of $0.18. Revenue for the quarter came in at $59.7 million versus the consensus estimate of $55.28 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• Corona-maker Constellation Brands beats estimates, shares jump 2%
• Nike (NKE) PT Lowered to $60 at Guggenheim